Early Detection of Malignant Pleural Mesothelioma in Asbestos-Exposed Individuals with a Noninvasive Proteomics-Based Surveillance Tool

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Ostroff, Rachel M ^a   Mehan, Michael R ^a   Stewart, Alex ^a   Ayers, Deborah ^a   Brody, Edward N ^a   Williams, Stephen A ^a   Levin, Stephen ^b   Black, Brad ^c   Harbut, Michael ^d   Carbone, Michele ^e   Goparaju, Chandra ^f   Pass, Harvey I ^f  

^a SomaLogic Inc   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c Center for Asbestos Related Disease   (United States)

^d KARMANOS CANCER INSTITUTE   (United States)

^e UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^f NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; ASBESTOS; BLOOD CLOTTING FACTOR 9; CASPASE 9; CCL23 CHEMOKINE; CD30 ANTIGEN; CHEMOKINE; COMPLEMENT COMPONENT C9; CXCL13 CHEMOKINE; CYCLIN DEPENDENT KINASE 5; FIBRONECTIN; INTERCELLULAR ADHESION MOLECULE 2; KALLISTATIN; MESOTHELIN; MIDKINE; SERINE PROTEINASE INHIBITOR; STEM CELL FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASBESTOSIS; ASSAY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RISK; CANCER STAGING; CARCINOGENICITY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; EARLY DIAGNOSIS; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NON INVASIVE PROCEDURE; NUCLEOTIDE SEQUENCE; OCCUPATIONAL EXPOSURE; PLEURA MESOTHELIOMA; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEOMICS; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; ASBESTOS; CARCINOGENS; CASE-CONTROL STUDIES; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LECTINS; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; PRINCIPAL COMPONENT ANALYSIS; PROTEOMICS; PUBLIC HEALTH SURVEILLANCE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84867068847     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046091     Document Type: Article

References (24)

1. Carbone M, Ly BH, Dodson RF, Pagano I, Morris PT, et al. (2012) Malignant mesothelioma: facts, myths, and hypotheses. J Cell Physiol 227: 44-58 10.1002/jcp.22724 [doi].
2. Pass HI, Carbone M, (2009) Current status of screening for malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 21: 97-104 S1043-0679(09)00071-9 [pii];10.1053/j.semtcvs.2009.06.007 [doi].
3. Roberts HC, Patsios DA, Paul NS, DePerrot M, Teel W, et al. (2009) Screening for malignant pleural mesothelioma and lung cancer in individuals with a history of asbestos exposure. J Thorac Oncol 4: 620-628 10.1097/JTO.0b013e31819f2e0e [doi].
4. Vierikko T, Jarvenpaa R, Autti T, Oksa P, Huuskonen M, et al. (2007) Chest CT screening of asbestos-exposed workers: lung lesions and incidental findings. Eur Respir J 29: 78-84 09031936.00073606 [pii];10.1183/09031936.00073606 [doi].
5. Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, et al. (2008) Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg 85: 265-272 S0003-4975(07)01570-6 [pii];10.1016/j.athoracsur.2007.07.042 [doi].
6. Pass HI, Lott D, Lonardo F, Harbut M, Liu Z, et al. (2005) Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 353: 1564-1573 353/15/1564 [pii];10.1056/NEJMoa051185 [doi].
7. Creaney J, Robinson BW, (2009) Serum and pleural fluid biomarkers for mesothelioma. Curr Opin Pulm Med 15: 366-370 10.1097/MCP.0b013e32832b98eb [doi].
8. Hollevoet K, Reitsma JB, Creaney J, Grigoriu BD, Robinson B, et al. (2012) Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol 30.
9. Creaney J, Olsen NJ, Brims F, Dick IM, Musk AW, et al. (2010) Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma. Cancer Epidemiol Biomarkers Prev 19: 2238-2246 1055-9965.EPI-10-0346 [pii];10.1158/1055-9965.EPI-10-0346 [doi].
10. Santarelli L, Strafella E, Staffolani S, Amati M, Emanuelli M, et al. (2011) Association of MiR-126 with soluble mesothelin-related peptides, a marker for malignant mesothelioma. PLoS One 6: e18232 10.1371/journal.pone.0018232 [doi].
11. Pass HI, Goparaju C, Ivanov S, Donington J, Carbone M, et al. (2010) hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma. Cancer Res 70: 1916-1924 0008-5472.CAN-09-3993 [pii];10.1158/0008-5472.CAN-09-3993 [doi].
12. Gold L, Ayers D, Bertino J, Bock C, Bock A, et al. (2010) Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS One 5: e15004 10.1371/journal.pone.0015004 [doi].
13. Vaught JD, Bock C, Carter J, Fitzwater T, Otis M, et al. (2010) Expanding the chemistry of DNA for in vitro selection. J Am Chem Soc 132: 4141-4151 10.1021/ja908035g [doi].
14. Kraemer S, Vaught JD, Bock C, Gold L, Katilius E, et al. (2011) From SOMAmer-based biomarker discovery to diagnostic and clinical applications: a SOMAmer-based, streamlined multiplex proteomic assay. PLoS One 6: e26332 10.1371/journal.pone.0026332 [doi];PONE-D-10-01799 [pii].
15. Selikoff IJ, Seidman H, (1992) Use of death certificates in epidemiological studies, including occupational hazards: variations in discordance of different asbestos-associated diseases on best evidence ascertainment. Am J Ind Med 22: 481-492.
16. Tuck MK, Chan DW, Chia D, Godwin AK, Grizzle WE, et al. (2009) Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J Proteome Res 8: 113-117 10.1021/pr800545q [doi];10.1021/pr800545q [pii].
17. Huang dW, Sherman BT, Lempicki RA, (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57 nprot.2008.211 [pii];10.1038/nprot.2008.211 [doi].
18. Ostroff R, Foreman T, Keeney TR, Stratford S, Walker JJ, et al. (2010) The stability of the circulating human proteome to variations in sample collection and handling procedures measured with an aptamer-based proteomics array. J Proteomics 73: 649-666 S1874-3919(09)00252-8 [pii];10.1016/j.jprot.2009.09.004 [doi].
19. Breiman L, (2001) Random forests. Machine Learning 45: 5-32 10.1023/A:1010933404324.
20. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD, (2008) Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 100: 1432-1438 djn326 [pii];10.1093/jnci/djn326 [doi].
21. Pinato DJ, Mauri FA, Ramakrishnan R, Wahab L, Lloyd T, et al. (2012) Inflammation-based prognostic indices in malignant pleural mesothelioma. J Thorac Oncol 7: 587-594 10.1097/JTO.0b013e31823f45c1 [doi].
22. Carbone M, Baris YI, Bertino P, Brass B, Comertpay S, et al. (2011) Erionite exposure in North Dakota and Turkish villages with mesothelioma. Proc Natl Acad Sci U S A 108: 13618-13623 1105887108 [pii];10.1073/pnas.1105887108 [doi].
23. Chee J, Singh J, Naran A, Misso NL, Thompson PJ, et al. (2007) Novel expression of kallikreins, kallikrein-related peptidases and kinin receptors in human pleural mesothelioma. Biol Chem 388: 1235-1242 10.1515/BC.2007.139 [doi].
24. Miao RQ, Chen V, Chao L, Chao J, (2003) Structural elements of kallistatin required for inhibition of angiogenesis. Am J Physiol Cell Physiol 284: C1604-C1613 10.1152/ajpgi.00524.2002 [doi];284/6/C1604 [pii].